Literature DB >> 25267903

Fixed-dose combination therapy for the prevention of cardiovascular disease.

Angharad N de Cates1, Matthew Rb Farr1, Karen Rees1, Juan P Casas2, Mark Huffman3.   

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To determine the effectiveness of fixed-dose combination therapy on optimising CVD risk factors and reducing CVD fatal and non-fatal events for both primary and secondary prevention of CVD. Details of CVD events and risk factors included are listed in the methods. We will also determine any adverse events associated with taking fixed-dose combination therapy. This will include studies conducted in both developed and developing regions of the world.

Entities:  

Year:  2012        PMID: 25267903      PMCID: PMC4176631          DOI: 10.1002/14651858.CD009868

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  53 in total

Review 1.  The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions.

Authors:  Eva Lonn; Jackie Bosch; Koon K Teo; Prem Pais; Denis Xavier; Salim Yusuf
Journal:  Circulation       Date:  2010-11-16       Impact factor: 29.690

2.  Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.

Authors:  S Yusuf; P Pais; R Afzal; D Xavier; K Teo; J Eikelboom; A Sigamani; V Mohan; R Gupta; N Thomas
Journal:  Lancet       Date:  2009-03-30       Impact factor: 79.321

3.  WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE (WHO-PREMISE).

Authors:  Shanthi Mendis; Dele Abegunde; Salim Yusuf; Shah Ebrahim; Gerry Shaper; Hassen Ghannem; Bakuti Shengelia
Journal:  Bull World Health Organ       Date:  2005-11-10       Impact factor: 9.408

4.  Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.

Authors:  Martin J O'Donnell; Denis Xavier; Lisheng Liu; Hongye Zhang; Siu Lim Chin; Purnima Rao-Melacini; Sumathy Rangarajan; Shofiqul Islam; Prem Pais; Matthew J McQueen; Charles Mondo; Albertino Damasceno; Patricio Lopez-Jaramillo; Graeme J Hankey; Antonio L Dans; Khalid Yusoff; Thomas Truelsen; Hans-Christoph Diener; Ralph L Sacco; Danuta Ryglewicz; Anna Czlonkowska; Christian Weimar; Xingyu Wang; Salim Yusuf
Journal:  Lancet       Date:  2010-06-17       Impact factor: 79.321

Review 5.  The Polymeal: a more natural, safer, and probably tastier (than the Polypill) strategy to reduce cardiovascular disease by more than 75%.

Authors:  Oscar H Franco; Luc Bonneux; Chris de Laet; Anna Peeters; Ewout W Steyerberg; Johan P Mackenbach
Journal:  BMJ       Date:  2004-12-18

6.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

7.  EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries.

Authors:  Kornelia Kotseva; David Wood; Guy De Backer; Dirk De Bacquer; Kalevi Pyörälä; Ulrich Keil
Journal:  Eur J Cardiovasc Prev Rehabil       Date:  2009-04

8.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321

9.  Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials.

Authors:  Colin Baigent; Lisa Blackwell; Rory Collins; Jonathan Emberson; Jon Godwin; Richard Peto; Julie Buring; Charles Hennekens; Patricia Kearney; Tom Meade; Carlo Patrono; Maria Carla Roncaglioni; Alberto Zanchetti
Journal:  Lancet       Date:  2009-05-30       Impact factor: 79.321

10.  Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Vasilios Papademetriou; Linda B Piller; Charles E Ford; David Gordon; Thomas J Hartney; Therese S Geraci; Efrain Reisin; Brian Montgomery Sumner; Nathan D Wong; Chuke Nwachuku; Puneet Narayan; Julian Haywood; Gabriel Habib
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Nov-Dec       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.